[1] P. Cairns, Renal cell carcinoma, Cancer Biomark, 9 (2010) 461-473.
[2] R.E. Gray, G.T. Harris, Renal Cell Carcinoma: Diagnosis and Management, Am Fam Physician, 99 (2019) 179-184.
[3] A. Deleuze, J. Saout, F. Dugay, B. Peyronnet, R. Mathieu, G. Verhoest, K. Bensalah, L. Crouzet, B. Laguerre, M.A. Belaud-Rotureau, N. Rioux-Leclercq, S.F. Kammerer-Jacquet, Immunotherapy in Renal Cell Carcinoma: The Future Is Now, Int J Mol Sci, 21 (2020).
[4] C. Holtstrater, B. Schrors, T. Bukur, M. Lower, Bioinformatics for Cancer Immunotherapy, Methods Mol Biol, 2120 (2020) 1-9.
[5] M.L. Gumz, H. Zou, P.A. Kreinest, A.C. Childs, L.S. Belmonte, S.N. LeGrand, K.J. Wu, B.A. Luxon, M. Sinha, A.S. Parker, L.Z. Sun, D.A. Ahlquist, C.G. Wood, J.A. Copland, Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma, Clin Cancer Res, 13 (2007) 4740-4749.
[6] C.A. von Roemeling, D.C. Radisky, L.A. Marlow, S.J. Cooper, S.K. Grebe, P.Z. Anastasiadis, H.W. Tun, J.A. Copland, Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4, Cancer Res, 74 (2014) 4796-4810.
[7] Z. Wotschofsky, L. Gummlich, J. Liep, C. Stephan, E. Kilic, K. Jung, J.N. Billaud, H.A. Meyer, Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p, PLoS One, 11 (2016) e0148746.
[8] J. Liep, E. Kilic, H.A. Meyer, J. Busch, K. Jung, A. Rabien, Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma, PLoS One, 11 (2016) e0157801.
[9] C. The Gene Ontology, The Gene Ontology Resource: 20 years and still GOing strong, Nucleic Acids Res, 47 (2019) D330-D338.
[10] A. Lameirinhas, V. Miranda-Goncalves, R. Henrique, C. Jeronimo, The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma, Genes (Basel), 10 (2019).
[11] S.N. Shi, X. Qin, S. Wang, W.F. Wang, Y.F. Zhu, Y. Lin, Z.L. Zhou, B.K. Shi, X.G. Liu, Identification of potential novel differentially-expressed genes and their role in invasion and migration in renal cell carcinoma, Aging (Albany NY), 12 (2020) 9205-9223.
[12] P. Wu, T. Xiang, J. Wang, R. Lv, G. Wu, TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma, FEBS Open Bio, 10 (2020) 2588-2604.
[13] W.H. Xu, Y. Xu, J. Wang, F.N. Wan, H.K. Wang, D.L. Cao, G.H. Shi, Y.Y. Qu, H.L. Zhang, D.W. Ye, Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment, Aging (Albany NY), 11 (2019) 6999-7020.
[14] Y. Luo, D. Shen, L. Chen, G. Wang, X. Liu, K. Qian, Y. Xiao, X. Wang, L. Ju, Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma, Aging (Albany NY), 11 (2019) 6029-6052.
[15] E.D. Montal, R. Dewi, K. Bhalla, L. Ou, B.J. Hwang, A.E. Ropell, C. Gordon, W.J. Liu, R.J. DeBerardinis, J. Sudderth, W. Twaddel, L.G. Boros, K.R. Shroyer, S. Duraisamy, R. Drapkin, R.S. Powers, J.M. Rohde, M.B. Boxer, K.K. Wong, G.D. Girnun, PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth, Mol Cell, 60 (2015) 571-583.
[16] M.X. Liu, L. Jin, S.J. Sun, P. Liu, X. Feng, Z.L. Cheng, W.R. Liu, K.L. Guan, Y.H. Shi, H.X. Yuan, Y. Xiong, Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma, Oncogene, 37 (2018) 1637-1653.
[17] K. Zou, Y. Hu, M. Li, H. Wang, Y. Zhang, L. Huang, Y. Xie, S. Li, X. Dai, W. Xu, Z. Ke, S. Gong, Y. Wang, Potential Role of HMGCS2 in Tumor Angiogenesis in Colorectal Cancer and Its Potential Use as a Diagnostic Marker, Can J Gastroenterol Hepatol, 2019 (2019) 8348967.
[18] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell, 144 (2011) 646-674.
[19] O. Abu Aboud, S.L. Habib, J. Trott, B. Stewart, S. Liang, A.J. Chaudhari, J. Sutcliffe, R.H. Weiss, Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging, Cancer Res, 77 (2017) 6746-6758.
[20] Z.P. Lin, M.F. Belcourt, J.G. Cory, A.C. Sartorelli, Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors, J Biol Chem, 279 (2004) 27030-27038.
[21] Y. Yang, J. Lin, S. Guo, X. Xue, Y. Wang, S. Qiu, J. Cui, L. Ma, X. Zhang, J. Wang, RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer, Cancer Cell Int, 20 (2020) 587.
[22] Y. Zhan, L. Jiang, X. Jin, S. Ying, Z. Wu, L. Wang, W. Yu, J. Tong, L. Zhang, Y. Lou, Y. Qiu, Inhibiting RRM2 to enhance the anticancer activity of chemotherapy, Biomed Pharmacother, 133 (2021) 110996.
[23] K.R. Leite, S.T. Reis, J.P. Junior, M. Zerati, O. Gomes Dde, L.H. Camara-Lopes, M. Srougi, PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis, Diagn Pathol, 10 (2015) 189.